Affinia Therapeutics

The company operates in the rapidly expanding market of gene therapy, which involves modifying or introducing genes into a patient's cells to treat or prevent disease. Affinia Therapeutics is at the forefront of this field, using its proprietary Affinia Rationally-designed Therapies (ART) platform to design the gene therapies of the future. This platform allows the company to understand how the structure of a gene impacts its function, enabling them to create more effective treatments.

Affinia Therapeutics' business model is centered around the development and commercialization of these gene therapies. The company creates libraries of adeno-associated viruses (AAVs), which are commonly used in gene therapy due to their ability to deliver genes to cells. By developing new AAVs, Affinia Therapeutics is able to expand the possibilities of gene therapy and create transformative medicines for people in need.

The company's clients are primarily patients suffering from devastating diseases, for whom traditional treatments have been ineffective. By providing these patients with innovative gene therapies, Affinia Therapeutics is able to make a lasting positive impact on their lives.

In terms of revenue, Affinia Therapeutics likely makes money by selling its gene therapies to healthcare providers or directly to patients. As the company continues to develop and commercialize new therapies, its revenue potential in the growing gene therapy market is significant.